Atorvastatin treatment and vaccination efficacy

Completed

• Conditions: Hepatitis A; Infections and Infestations

• Registration Number: ISRCTN87984926
• Lead Sponsor: Geneva University Hospital (Switzerland)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2006-01-25
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 312

Inclusion Criteria

Men and women who were greater than 18 years old were eligible for inclusion if they had neither morbidities nor immunity to hepatitis A

Exclusion Criteria

1. Anti-hepatitis A antibodies greater than 10 IU/l
2. Hypercholesterolemia
3. Hepatitis
4. Myositis
5. Chronic alcohol abuse
6. Pregnant or breast-feeding women
7. Volunteers on drug therapy except oral contraceptives

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The main outcome variable was the achievement of antibody levels greater than 20 IU/l against the hepatitis A virus one month after vaccination.

Secondary Outcome Measures

Name	Time	Method
1. A secondary outcome variable was the mean log-transformed antibody titre <br>2. To document the effects of atorvastatin on total blood cholesterol, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C), triglycerides, and high-sensitivity C-Reactive Protein (hs-CRP)